[go: up one dir, main page]

DE60316688D1 - Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon - Google Patents

Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon

Info

Publication number
DE60316688D1
DE60316688D1 DE60316688T DE60316688T DE60316688D1 DE 60316688 D1 DE60316688 D1 DE 60316688D1 DE 60316688 T DE60316688 T DE 60316688T DE 60316688 T DE60316688 T DE 60316688T DE 60316688 D1 DE60316688 D1 DE 60316688D1
Authority
DE
Germany
Prior art keywords
sub
dehydrophenylahistines
aldehyde
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60316688T
Other languages
English (en)
Other versions
DE60316688T2 (de
Inventor
Yoshio Hayashi
Jennifer Grodberg
Michael Palladino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nereus Pharmaceuticals Inc
Original Assignee
Nereus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nereus Pharmaceuticals Inc filed Critical Nereus Pharmaceuticals Inc
Publication of DE60316688D1 publication Critical patent/DE60316688D1/de
Application granted granted Critical
Publication of DE60316688T2 publication Critical patent/DE60316688T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
DE60316688T 2002-08-02 2003-08-01 Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon Expired - Lifetime DE60316688T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40107402P 2002-08-02 2002-08-02
US401074P 2002-08-02
US41112802P 2002-09-16 2002-09-16
US411128P 2002-09-16
US45006303P 2003-02-24 2003-02-24
US450063P 2003-02-24
PCT/US2003/024232 WO2004054498A2 (en) 2002-08-02 2003-08-01 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof

Publications (2)

Publication Number Publication Date
DE60316688D1 true DE60316688D1 (de) 2007-11-15
DE60316688T2 DE60316688T2 (de) 2008-07-17

Family

ID=32600863

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60316688T Expired - Lifetime DE60316688T2 (de) 2002-08-02 2003-08-01 Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon

Country Status (20)

Country Link
US (4) US7064201B2 (de)
EP (1) EP1529044B1 (de)
JP (1) JP4616649B2 (de)
KR (2) KR101184374B1 (de)
CN (1) CN100540548C (de)
AT (1) ATE374767T1 (de)
AU (1) AU2003302721B2 (de)
BR (2) BRPI0313363A8 (de)
CA (1) CA2494049C (de)
CO (1) CO5721010A2 (de)
DE (1) DE60316688T2 (de)
DK (1) DK1529044T5 (de)
ES (1) ES2295695T3 (de)
HK (2) HK1078080A1 (de)
IL (2) IL166628A0 (de)
MX (1) MXPA05001217A (de)
NZ (1) NZ538433A (de)
PT (1) PT1529044E (de)
WO (1) WO2004054498A2 (de)
ZA (1) ZA200501616B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026322B2 (en) * 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
BR0017067A (pt) * 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
US6555543B2 (en) 2000-08-04 2003-04-29 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
MXPA05001217A (es) 2002-08-02 2005-05-16 Nereus Pharmaceuticals Inc Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
DK1571970T3 (da) 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
CN102210852B (zh) 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
CA2553630A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CA2589828C (en) * 2004-12-06 2014-07-08 Newsouth Innovations Pty Limited Compositions comprising a taxoid and a benzimidazole carbamate for the treatment of cancer
US7732605B2 (en) 2005-03-29 2010-06-08 Nereus Pharmaceuticals, Inc. Synthesis of diketopiperazines
JP2008024871A (ja) * 2006-07-24 2008-02-07 Fujifilm Corp インク組成物、インクジェット記録方法、印刷物、平版印刷版の製造方法、及び平版印刷版
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2300011A4 (de) 2008-05-27 2012-06-20 Dmi Life Sciences Inc Therapeutische verfahren und verbindungen
WO2010059589A1 (en) * 2008-11-21 2010-05-27 Isis Pharmaceuticals, Inc. Anticancer combination comprising docetaxel and an antisense oligonucleotide
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
AU2012323320B2 (en) 2011-10-10 2017-05-11 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
PH12014500715A1 (en) 2011-10-28 2014-05-12 Ampio Pharmaceuticals Inc Treatment of rhinitis
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2968315B1 (de) 2013-03-15 2020-06-03 Ampio Pharmaceuticals, Inc. Zusammensetzungen für mobilisierung, homing, expansion und differenzierung von stammzellen und verfahren zur verwendung davon
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
NZ719049A (en) 2013-10-11 2020-06-26 Beyondspring Inc Cancer treatment with combination of plinabulin and taxane
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
CA2975729A1 (en) * 2015-02-12 2016-08-18 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
KR102626155B1 (ko) 2015-03-06 2024-01-17 비욘드스프링 파마수티컬스, 인코포레이티드. Ras 돌연변이와 관련된 암의 치료 방법
SG11201707128TA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating a brain tumor
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
EP3310375A4 (de) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Verwendung von niedermolekularen fraktionen von humanem serumalbumin bei der behandlung von erkrankungen
MY181892A (en) * 2015-07-13 2021-01-12 Beyondspring Pharmaceuticals Inc Plinabulin compositions
JP2019511565A (ja) 2016-02-08 2019-04-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド ツカレゾールまたはそのアナログを含む組成物
IL263439B1 (en) 2016-06-06 2025-02-01 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
CN114276332B (zh) * 2016-08-12 2023-08-18 深圳华大海洋科技有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备纯化方法和应用
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
CN107778297B (zh) * 2016-08-12 2021-11-19 深圳华大海洋科技有限公司 氘代脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法和应用
CN107011322B (zh) * 2016-08-12 2020-02-18 青岛海洋生物医药研究院股份有限公司 一种脱氢苯基阿夕斯丁类化合物的制备纯化方法
CN106565685B (zh) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
CN106565686B (zh) 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia
JP7280192B2 (ja) 2017-03-13 2023-05-23 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリン組成物及びその使用
CN108658945B (zh) * 2017-03-31 2020-11-20 深圳海王医药科技研究院有限公司 一种微管蛋白抑制剂（vda-1）的a晶型
WO2019028144A1 (en) 2017-08-03 2019-02-07 Teva Pharmaceuticals Usa, Inc. SALTS AND FORMS IN THE SOLID STATE OF PLINABULIN
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
CN111018840B (zh) * 2017-10-25 2022-09-09 西南大学 3-咪唑取代的靛红唑醇类化合物及其制备方法和医药应用
CN112135614A (zh) 2018-01-24 2020-12-25 大连万春布林医药有限公司 通过施用普那布林减少血小板减少症的组合物和方法
CN108299399A (zh) * 2018-02-01 2018-07-20 深圳海王医药科技研究院有限公司 一种小分子免疫化合物的晶型、其制备方法和含有其的药物组合物
MX2020012799A (es) * 2018-06-01 2021-03-25 Beyondspring Pharmaceuticals Inc Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
CN109030642B (zh) * 2018-06-26 2021-03-09 深圳海王医药科技研究院有限公司 一种脱氢苯基阿夕斯丁类似物及其异构体的测定方法
CN111840291B (zh) * 2020-07-14 2021-12-21 深圳海王医药科技研究院有限公司 一种在肿瘤治疗中具有增效作用的化合物的应用
CN117164560A (zh) * 2022-06-02 2023-12-05 上海旭成医药科技有限公司 哌嗪酮类化合物及其制备方法和用途
WO2024191805A1 (en) 2023-03-10 2024-09-19 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
WO1994012030A1 (en) * 1992-11-27 1994-06-09 Napro Biotherapeutics, Inc. Injectable composition
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
GB9402809D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) * 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) * 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) * 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
IL136044A (en) * 1997-11-21 2005-08-31 Euro Celtique Sa 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
IL137571A0 (en) 1998-01-29 2001-07-24 Aventis Pharm Prod Inc Method for preparing an n-[(aliphatic or aromatic)carboxyl]-2-aminoacetamide compound and a cyclyzed compound
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
AU752005B2 (en) * 1998-03-26 2002-09-05 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) * 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7026322B2 (en) * 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) * 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
BR0017067A (pt) * 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
WO2002064592A1 (en) * 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US6569556B2 (en) * 2001-01-29 2003-05-27 General Motors Corporation Cooling system for a battery pack
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
MXPA05001217A (es) * 2002-08-02 2005-05-16 Nereus Pharmaceuticals Inc Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CA2553630A1 (en) 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use

Also Published As

Publication number Publication date
US7674903B2 (en) 2010-03-09
DK1529044T3 (da) 2008-02-04
KR20050083610A (ko) 2005-08-26
CN100540548C (zh) 2009-09-16
HK1084388A1 (en) 2006-07-28
BR0313363A (pt) 2005-08-09
EP1529044B1 (de) 2007-10-03
CO5721010A2 (es) 2007-01-31
IL166628A (en) 2012-08-30
CN1684955A (zh) 2005-10-19
KR20110039500A (ko) 2011-04-18
CA2494049A1 (en) 2004-07-01
US20050090667A1 (en) 2005-04-28
KR101184374B1 (ko) 2012-09-20
MXPA05001217A (es) 2005-05-16
EP1529044A2 (de) 2005-05-11
US20060223822A1 (en) 2006-10-05
HK1078080A1 (en) 2006-03-03
KR101049100B1 (ko) 2011-07-15
CA2494049C (en) 2011-10-18
JP2006511534A (ja) 2006-04-06
PT1529044E (pt) 2008-01-14
WO2004054498A3 (en) 2004-11-25
US20060223823A1 (en) 2006-10-05
US20060217553A1 (en) 2006-09-28
US7064201B2 (en) 2006-06-20
AU2003302721B2 (en) 2009-10-08
DE60316688T2 (de) 2008-07-17
ZA200501616B (en) 2005-11-30
ATE374767T1 (de) 2007-10-15
ES2295695T3 (es) 2008-04-16
JP4616649B2 (ja) 2011-01-19
BRPI0313363A8 (pt) 2019-01-02
US7956058B2 (en) 2011-06-07
NZ538433A (en) 2008-02-29
WO2004054498A2 (en) 2004-07-01
DK1529044T5 (da) 2008-04-21
IL166628A0 (en) 2006-01-15
AU2003302721A1 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
DE60316688D1 (de) Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
ATE489365T1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
ATE462429T1 (de) Verbindungen mit fungizider wirkung und verfahren zur ihrer herstellung und verwendung
ATE389678T1 (de) Verfahren zur herstellung von wässrigen dispersionen
ATE506356T1 (de) Verfahren zur herstellung von 3-halo-4,5-dihydro- 1h-pyrazolen
SG158848A1 (en) Method for producing annelated piperazin-2-one derivatives and intermediates of said method
ATE501264T1 (de) Enzymatische verfahren zur herstellung 4- substituierter 3-hydroxybuttersäure-derivate
DE602004005888D1 (de) Herstellung von selbstorganisierten monoschichten
DE502004004681D1 (de) Verfahren zur herstellung von salzen schwach koordinierender aniomen, derartige salze sowie deren verwendung
ITMI20022076A1 (it) Sali di intermedi del cefdinir.
EP1247791A4 (de) Verfahren zur herstellung von perfluoroalkadienen
ATE359272T1 (de) Verfahren zur herstellung von 3-hydroxy-n-1,6-
WO2003068784A3 (de) Acyl- und bisacylphosphinderivate
ATE415404T1 (de) Lösungsmittelfreies verfahren zur herstellung von diketopyrrolopyrrol-derivaten
DE60105314D1 (de) Verfahren zur herstellung von taxanderivaten
DE60015563D1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
ATE310735T1 (de) Verfahren zur herstellung von spirocyclischen tetronsäurederivaten
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
DE60106778D1 (de) Verfahren zur herstellung von vitronectin-rezeptorantagonisten
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
ATE330612T1 (de) Verfahren zur herstellung von benazeprilhydrochloride
ATE515502T1 (de) Verfahren zur herstellung von tetranorlabdanderivaten
DE50204538D1 (de) Verfahren zur herstellung von biperiden iv
DE10336716A1 (de) Verfahren zur Herstellung von N-Aryl-morpholinonen
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition